Current and future status of JAK inhibitors
This paper provides an expert, up-to-date overview of JAK inhibitors, highlighting use in haematology-oncology, rheumatology, dermatology, and gastroenterology, and discusses how this complex therapeutic field might develop.
Source:
The Lancet
SPS commentary:
Globally, licensed JAK inhibitors include tofacitinib, ruxolitinib, upadacitinib, baricitinib, peficitinib and fedratinib (latter two agents not licensed in UK)